KLRS

Kalaris Therapeutics, Inc. NGM · KLRS

$4.38 -0.23 (-4.99%)

Neutral · -0.36σ Grade A

+ Compare Open in Sniper

Valuation

Market cap $0.1B

P/E (ttm) —

Forward P/E -2.7

Beta (5y) —

Shares out 23.8M

Div yield —

Profitability & returns

ROE -66.6%

Net margin —

FCF margin —

Debt / equity 0.02

Trading information

Last price $4.38

Day range $4.30 – $6.25

52-wk range $3.90 – $11.22

Avg volume 0.3M

RSI (2) 19.9

Trend zone Neutral

52-week range · today's price

$3.90$11.22

Company

Sector Healthcare

Industry Biotechnology

Exchange NGM

Next earnings —

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular ret…